Immunocore Holdings plc
Moat Score — Immunocore Holdings plc
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 5 / 5 | Immunocore's ImmTAX platform for engineering soluble, bispecific T cell receptors represents genuinely proprietary, hard-to-replicate biological engineering, protected by a deep patent estate and validated by KIMMTRAK's real-world regulatory approvals in 39 countries. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a commercial-stage biotech reliant on outsourced contract manufacturers (AGC Biologics, Simtra) and a hybrid sales infrastructure, Immunocore has no low-cost positioning; its economics are driven by premium rare-disease pricing, not production efficiency. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | As the only approved therapy for HLA-A*02:01-positive metastatic uveal melanoma, KIMMTRAK commands significant pricing power in a rare-disease market with no FDA/EC-approved alternative, though this power is tempered by ongoing payer negotiations and partner-distributed international markets. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Immunocore's business does not benefit from network effects — each patient treatment, clinical trial, and regional launch is independently executed and does not become more valuable as more patients or physicians adopt the therapy. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Once a patient and physician commit to a KIMMTRAK treatment course there is practical continuity, but because it treats an acute/progressive rare cancer rather than a chronic condition requiring repeat purchasing decisions, there is limited structural switching-cost moat beyond the absence of alternatives. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | Uveal melanoma is a genuinely small, orphan-sized market that likely cannot support multiple competing approved therapies profitably, giving Immunocore a durable position in that niche, but its broader pipeline (melanoma, HIV, hepatitis B, autoimmune disease) targets much larger markets where efficient-scale protection is far less assured. |